Two more EU states–Belgium and the Netherlands–recently introduced “sunshine”rules designed to boost transparency into the medtech industry’s financial relationships with healthcare professionals. While this sounds like a noble endeavor, it creates challenges for those in the medtech industry–especially given the EU’s piecemeal approach to transparency. Companies are forced to address it on a country-by-country basis. In this Q&A article,attorneys Hein van den Bos and Ron Wisor discuss the implications of the sunshine requirements both in the EU and U.S., how they–and the regulatory environment in general–differ,and what the EU can learn from the U.S.